1) Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand
is constitutively secreted by prostate cancer cells in vitro. Clin
Cancer Res. 1998;4:1803-11.
2) Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein
S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P.
Constitutive and induced expression of APO-1, a new member
of the NGF/TNF receptor superfamily, in normal and neoplastic
cells. Lab Invest. 1993;69:415-29.
3) Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, Kawabe K.
Immunohistochemical study of Fas, Fas ligand and interleukin-1
beta converting enzyme expression in human prostatic cancer. Br
J Urol. 1998;81:852-5.
4) K im SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee
SH. Immunohistochemical analysis of Fas and FLIP in prostate
cancers. APMIS. 2009;117:28-33.
5) Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA,
Koch MO, Eble JN, Cheng L. Fas and Fas ligand expression is
elevated in prostatic intraepithelial neoplasia and prostatic
adenocarcinoma. Cancer. 2002;95:296-300.
6) K imura K, Gelmann EP. Tumor necrosis factor-alpha and Fas
activate complementary Fas-associated death domain-dependent
pathways that enhance apoptosis induced by gamma-irradiation.
J Biol Chem. 2000;275:8610-7.
7) Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y,
Meyn RE. TRA IL (APO-2L) induces apoptosis in human prostate
cancer cells inhibitable by Bcl-2. Oncogene. 2001;20:3757-65.
8) Nimmanapalli R, Perkins CL, Orlando M, O’Bryan E, Nguyen D,
Bhalla KN. Pretreatment with paclitaxel enhances Apo-2 ligand/
tumor necrosis factor-related apoptosisinducing ligand-induced
apoptosis of prostate cancer cells by inducing death receptors 4
and 5 protein levels. Cancer Res. 2001;61:759-63.
9) Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner
V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D,
French LE, Tschopp J. Inhibition of death receptor signals by
cellular FLIP. Nature. 1997;388:190-5.
10) Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA,
Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas MP,
Reed JC, Glinsky GV, Schimmer AD. Critical role for Fasassociated
death domain-like interleukin-1-converting enzymelike
inhibitory protein in anoikis resistance and distant tumor
formation. J Natl Cancer Inst. 2007;99:811-22.
11) Santourlidis S, Warskulat U, Florl AR, Maas S, Pulte T, Fischer J,
Müller W, Schulz WA. Hypermethylation of the tumor necrosis
factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene
promoter at rel/nuclear factor kB sites in prostatic carcinoma.
Mol Carcinog. 2001;32:36-43.
12) Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A,
Iannettoni MD, Orringer MB, Beer DG. Fas/APO-1 (CD95) is not
translocated to the cell membrane in esophageal adenocarcinoma.
Cancer Res. 1997;57:5571-8.
13) Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB,
Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary
adenocarcinomas. J Clin Invest. 1998;101:1102-10.
14) Higaki K, Yano H, Kojiro M. Fas antigen expression and its
relationship with apoptosis in human hepatocellular carcinoma
and noncancerous tissues. Am J Pathol. 1996;149:429-37.
15) Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the
stromal microenvironment in carcinogenesis of the prostate. Int J
Cancer. 2003;107:1-10.
16) Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS.
The gene expression program of prostate fibroblast senescence
modulates neoplastic epithelial cell proliferation through
paracrine mechanisms. Cancer Res. 2006;66:794-802.
17) Begley L, Keeney D, Beheshti B, Squire JA, Kant R, Chaib H,
MacDonald JW, Rhim J, Macoska JA. Concordant copy number
and transcriptional activity of genes mapping to derivative
chromosomes 8 during cellular immortalization in vitro. Genes
Chromosomes Cancer. 2006;45:136-46.
18) A nees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P,
Loda M, Lis R, Krainer M, Oh WK. Recurrence-free survival in
prostate cancer is related to increased stromal TRA IL expression.
Cancer. 2011;117:1172-82.
19) Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, Dong SM,
Na EY , Kim CS, Kim SH, Yoo NJ. In vivo expression of soluble
Fas and FAP-1: Possible mechanisms of Fas resistance in human
hepatoblastomas. J Pathol. 1999;188:207-12.
20) Sato T, Irie S, Kitada S, Reed JC. FAP-1: A protein tyrosine
phosphatase that associates with Fas. Science. 1995;268:411-5.
21) Thomas RK, Kallenborn A, Wickenhauser C, Schultze JL, Draube
A, Vockerodt M, Re D, Diehl V, Wolf J. Constitutive expression
of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol.
2002;160:1521-8.
22) R yu BK, Lee MG, Chi SG, Kim YW, Park JH. Increased expression
of cFLIP(L) in colonic adenocarcinoma. J Pathol. 2001;194:15-9.
23) Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ.
Intracellular regulation of TRA IL induced apoptosis in human
melanoma cells. J Immunol. 1998;161:2833-40.
24) Lee SH, Kim HS, Kim SY, Lee YS, Park WS, Kim SH, Lee JY, Yoo
NJ. Increased expression of FLIP, an inhibitor of Fas-mediated
apoptosis, in stomach cancer. APMIS. 2003;111:309-14.
25) Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi
AF. Persistent c-FLIP(L) expression is necessary and sufficient to
maintain resistance to tumor necrosis factor-related apoptosisinducing
ligand-mediated apoptosis in prostate cancer. Cancer
Res. 2004;64:7086-91.
26) Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY,
Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ, Lee SH. Alterations of
Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am
J Pathol. 1999;154:1785-91.
27) K im HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY,
Cho YG, Kim CJ, Jeong SW, Nam SW, Kim SH, Lee JY, Yoo NJ,
Lee SH. Inactivating mutations of caspase-8 gene in colorectal
carcinomas. Gastroenterology. 2003;125:708-15.
28) Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, Lee
JH, Park JY, Jang JJ, Kim CW, Kim SH, Lee JY, Yoo NJ, Lee
SH. Inactivating mutations of CASP10 gene in non-Hodgkin
lymphomas. Blood. 2002;99:4094-9.
29) Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand
is expressed in normal breast epithelial cells and is frequently upregulated
in breast cancer. J Pathol. 2000;190:20-30.
30) Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French
LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J,
Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand:
Implications for tumor immune escape. Science. 1996;274:1363-
6)
31) A shkenazi A, Dixit VM. Death receptors: Signaling and
modulation. Science. 1998;281:1305-8.
32) Griffith TS, Lynch DH. TRA IL: A molecule with multiple
receptors and control mechanisms. Curr Opin Immunol.
1998;10:559-63.
33) Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS.
Elevated AKT activity protects the prostate cancer cell line LNCaP
from TRA IL-induced apoptosis. J Biol Chem. 2001;276:10767-74.
34) Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M,
Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI,
Goddard AD, Godowski P, Ashkenazi A. Control of TRA ILinduced
apoptosis by a family of signaling and decoy receptors.
Science. 1997;277:818-21.
35) French LE, Tschopp J. The TRA IL to selective tumor death. Nat
Med. 1999;5:146-7.
36) Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G,
Sanlioglu S. Adenovirus-mediated IKKbetaKA expression
sensitizes prostate carcinoma cells to TRA IL-induced apoptosis.
Cancer Gene Ther. 2006;13:21-31.
37) Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S.
Surface TRA IL decoy receptor-4 expression is correlated with
TRA IL resistance in MCF7 breast cancer cells. BMC Cancer.
2005;5:54.
38) Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G,
Sanlioglu S. Differential expression of TRA IL and its receptors in
benign and malignant prostate tissues. J Urol. 2007;177:359-64.
39) Shankar S, Chen X, Srivastava RK. Effects of sequential treatments
with hemotherapeutic drugs followed by TRA IL on prostate
cancer in vitro and in vivo. Prostate. 2005;62:165-86.
40) Sridhar S, Ali AA, Liang Y, El Etreby MF, Lewis RW, Kumar MV.
Differential expression of members of the tumor necrosis factor
alpha-related apoptosis-inducing ligand pathway in prostate
cancer cells. Cancer Res. 2001;61:7179-83.
41) Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances
the therapeutic potential of TRA IL in prostate cancer in vitro and
in vivo: Intracellular mechanisms. Prostate. 2004;61:35-49.
42) Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley
DR. Reactive stroma in human prostate cancer: Induction of
myofibroblast phenotype and extracellular matrix remodeling.
Clin Cancer Res. 2002;8:2912-23.
43) Dean JP, Nelson PS. Profiling influences of senescent and aged
fibroblasts on prostate carcinogenesis. Br J Cancer. 2008;98:245-9.
44) Risbridger GP, Taylor RA . Minireview: Regulation of prostatic
stem cells by stromal niche in health and disease. Endocrinology.
2008;149:4303-6.
45) Shimada K, Nakamura M, Matsuyoshi S, Ishida E, Konishi N.
Specific positive and negative effects of FLIP on cell survival in
human prostate cancer. Carcinogenesis. 2006;27:1349-57.